The involvement of protein kinase C isoenzymes α, ε and ζ in the sensitivity to antitumor treatment and apoptosis induction

被引:0
作者
Spitaler, M
Wiesenhofer, B
Biedermann, V
Seppi, T
Zimmermann, J
Grunicke, H
Hofmann, J
机构
[1] Univ Innsbruck, Inst Med Chem & Biochem, A-6020 Innsbruck, Austria
[2] Univ Innsbruck, Dept Radiat Therapy, A-6020 Innsbruck, Austria
[3] Novartis Pharma AG, CH-4002 Basel, Switzerland
关键词
protein kinase C; isoenzymes; apoptosis; anticancer drugs; drug resistance;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In order to obtain additional information on the involvement of protein kinase C (PKC) isoenzymes in the resistance of cells to anticancer drugs and in the induction of apoptosis, we employed antisense oligonucleotides to PKC alpha and PKC zeta, CGP 53506, a new inhibitor of PKC alpha, and cells overexpressing PKC alpha, PKC epsilon and PKC zeta. We found that in HeLa cells which express PKC alpha and alpha, down-modulation of either PKC alpha or PKC zeta with antisense oligonucleotides induced apoptosis. The PKC alpha selective inhibitor CGP 53506 reduced the proliferation rate of PKC alpha overexpressing NIH3T3 cells more than that of wild-type cells and induced apoptosis. indicating that such a PKC alpha inhibitor may be useful in the treatment of tumors over expressing PKC alpha such as glioblastomas. NIH3T3 cells overexpressing PKC alpha were more resistant, whereas NIH3T3 cells overexpressing PKC epsilon or PKC zeta. were more sensitive to treatment with cis-platin, adriamycin or gamma-irradiation compared to parental NIH3T3 wild-type cells. The observed resistance and sensitization corresponded to the extent of apoptosis induced by these treatments. Alterations in the expression of p53, bcl-2 and bar in the PKC isoenzyme overexpressing cells indicate that these proteins may be involvd in the different sensitivities of these cells.
引用
收藏
页码:3969 / 3976
页数:8
相关论文
共 46 条
  • [1] Adams L. M., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P410
  • [2] ENHANCEMENT OF ANTITUMOR-ACTIVITY OF MITOMYCIN-C INVITRO AND INVIVO BY UCN-01, A SELECTIVE INHIBITOR OF PROTEIN-KINASE-C
    AKINAGA, S
    NOMURA, K
    GOMI, K
    OKABE, M
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1993, 32 (03) : 183 - 189
  • [3] INVASIVE HUMAN PITUITARY-TUMORS EXPRESS A POINT-MUTATED ALPHA-PROTEIN KINASE-C
    ALVARO, V
    LEVY, L
    DUBRAY, C
    ROCHE, A
    PEILLON, F
    QUERAT, B
    JOUBERT, D
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1993, 77 (05) : 1125 - 1129
  • [4] ONCOGENIC TRANSFORMATION ALTERS CISPLATIN-INDUCED APOPTOSIS IN RAT EMBRYO FIBROBLASTS
    BASU, A
    CLINE, JS
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1995, 63 (04) : 597 - 603
  • [5] THE POTENTIAL OF PROTEIN-KINASE-C AS A TARGET FOR ANTICANCER TREATMENT
    BASU, A
    [J]. PHARMACOLOGY & THERAPEUTICS, 1993, 59 (03) : 257 - 280
  • [6] COMPARISON OF PROTEIN-KINASE-C ACTIVITY AND ISOFORM EXPRESSION IN CISPLATIN-SENSITIVE AND CISPLATIN-RESISTANT OVARIAN-CARCINOMA CELLS
    BASU, A
    WEIXEL, KM
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1995, 62 (04) : 457 - 460
  • [7] Positioning atypical protein kinase C isoforms in the UV-induced apoptotic signaling cascade
    Berra, E
    Municio, MM
    Sanz, L
    Frutos, S
    DiazMeco, MT
    Moscat, J
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1997, 17 (08) : 4346 - 4354
  • [8] Blagosklonny MV, 1997, CANCER RES, V57, P130
  • [9] REGULATION OF PROTEIN-KINASE-C AND ROLE IN CANCER BIOLOGY
    BLOBE, GC
    OBEID, LM
    HANNUN, YA
    [J]. CANCER AND METASTASIS REVIEWS, 1994, 13 (3-4) : 411 - 431
  • [10] Chakrabarty S, 1996, J Exp Ther Oncol, V1, P218